AFP and hepatocellular carcinoma: Even though the median serum levels of both biomarkers were significantly higher in cirrhotic patients with HCC compared to those without HCC, the diagnostic accuracy of each biomarker for the diagnosis of HCC was estimated moderate in early‐stage HCC (AUROC 65.8% for AFP and 65% for PIVKA‐II in BCLC‐0/A patients), good in BCLC‐B stage (86.4% for AFP and 79.5% for PIVKA‐II), and was excellent among BCLC‐C stage HCC patients (AUROC 94.3% for AFP and 91.3% for PIVKA‐II).